Association of improved pulmonary phenotype in Irish cystic fibrosis patients with a 3' enhancer polymorphism in alpha-1-antitrypsin

Pediatric Pulmonology
Julia M CourtneyClare M O'Connor

Abstract

Modifier genes other than CFTR are thought to influence lung disease phenotype in cystic fibrosis (CF). In this study, we investigated the relationship between a polymorphism (1237 G --> A) in the 3' enhancer region of the alpha-1-antitrypsin (AAT) gene and pulmonary disease severity in 320 CF patients recruited from two independent adult referral centers in Ireland, and evaluated the in vivo effect of the polymorphism on AAT levels during acute infection. When corrected for confounding variables, the polymorphism was found to make a small but significant contribution to variance in percent predicted forced expired volume in 1 sec (FEV1) (1.1%, P = 0.05), with possession of the A allele being associated with better pulmonary function (AA/AG genotype: percent predicted FEV1, 70.8 +/- 3.9; GG genotype: percent predicted FEV1, 62.0 +/- 1.4). As would be expected of a modifier effect, the influence of the polymorphism was more marked in patient groups traditionally associated with more severe lung disease, contributing 3.2% (P = 0.033) to the variance in percent predicted FEV1 in patients homozygous for DF508, 3.3% (P = 0.007) to those infected with Pseudomonas aeruginosa, and 3% (P = 0.024) in female patients. In each instance, a ...Continue Reading

References

Jul 13, 1995·The New England Journal of Medicine·K H GanH G Heijerman
Nov 1, 1996·American Journal of Respiratory and Critical Care Medicine·P B DavisM W Konstan
Jun 12, 1998·The European Respiratory Journal·R MahadevaD A Lomas
May 6, 1999·American Journal of Respiratory and Critical Care Medicine·A J SandfordP D Paré
May 19, 2000·Thorax·R Mahadeva, D A Lomas
Apr 21, 2001·European Journal of Human Genetics : EJHG·M T HenryN Kalsheker
Nov 1, 2001·Respiratory Research·M L Drumm
Jul 19, 2002·American Journal of Medical Genetics·Francesco SalvatoreGiuseppe Castaldo
Feb 25, 2003·Lancet·Lon R Cardon, Lyle J Palmer
Apr 5, 2003·The Journal of Laboratory and Clinical Medicine·Christian A Merlo, Michael P Boyle
Apr 12, 2003·American Journal of Respiratory Cell and Molecular Biology·Despina D FrangoliasAndrew J Sandford
Aug 28, 2003·Annals of Human Genetics·Rebecca K Rowntree, Ann Harris
Oct 7, 2005·The New England Journal of Medicine·Mitchell L DrummUNKNOWN Gene Modifier Study Group

❮ Previous
Next ❯

Citations

Jun 20, 2008·Genes and Immunity·A D HillianUNKNOWN CF Gene Modifier Study Group
Oct 21, 2006·Current Opinion in Pulmonary Medicine·Michael R Knowles
Sep 25, 2008·Current Opinion in Pulmonary Medicine·Joseph M Collaco, Garry R Cutting
Feb 27, 2014·The International Journal of Biochemistry & Cell Biology·Loic GuillotHarriet Corvol

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.